Jakhongir Gulomovich Khaydarov

Dr. Jakhongir Gulomovich Khaydarov

Internal Diseases in Family Medicine No. 1, Tashkent State Medical University, Tashkent, Toshkent, Uzbekistan
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
Muborakkhon ZokirovaMuborakkhon Zokirova
Muborakkhon Zokirova
AKAbdurakhman Kayumov
Abdurakhman Kayumov
NNNargiza Nurillaeva
Nargiza Nurillaeva
Jakhongir Gulomovich KhaydarovJakhongir Gulomovich Khaydarov
Jakhongir Gulomovich Khaydarov
Background: Cardiotoxic complications represent a major challenge in patients receiving anticancer therapy and may be influenced by interactions among demographic and genetic factors contributing to structural, functional, and electrophysiological myocardial abnormalities. This study aimed to evaluate the effects of age, sex, and genetic polymorphisms on the development of cardiotoxic complications in patients with acute leukemia. Methods: A total of 89 patients aged 18–78 years underwent electrocardiography, echocardiography, and molecular genetic analyses of polymorphisms in GPX4, SOD2, COL1A1, CAT, EDN1, and COMT. Results: Left ventricular hypertrophy (LVH) was detected in 58.4% of patients, reduced left ventricular ejection fraction (LVEF < 50%) in 23.6%, arrhythmias in 46.1%, and ischemic myocardial changes in 28.1%. Older age was significantly associated with LVH, reduced LVEF, and ischemic myocardial changes (all p < 0.05). Sex-specific differences showed a higher prevalence of rhythm disturbances in women and ischemic myocardial changes in men than in women. Individual genetic polymorphisms were significantly associated with specific cardiac phenotypes. Furthermore, combined genetic risk, defined as the presence of two or more unfavorable alleles, was significantly associated with higher rates of LVH, arrhythmias, and impaired myocardial contractility. Multivariate logistic regression identified COMT Val158Met, COL1A1 C1997A, SOD2 C14510A, and EDN1 Lys198Asn as independent genetic predictors of cardiotoxic complications. Conclusions: These findings support a polygenic model of cardiotoxicity and highlight the potential value of integrating demographic and genetic factors for personalized cardiovascular risk stratification, early detection, and prevention of treatment-related cardiac complications.

1 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Muborakkhon ZokirovaMuborakkhon Zokirova
Muborakkhon Zokirova
AKAbdurakhman Kayumov
Abdurakhman Kayumov
NNNargiza Nurillaeva
Nargiza Nurillaeva
Jakhongir Gulomovich KhaydarovJakhongir Gulomovich Khaydarov
Jakhongir Gulomovich Khaydarov
Cardiotoxic complications are influenced by demographic and genetic factors that contribute to myocardial structural and electrophysiological abnormalities. This study aimed to assess the impact of age, sex, and genetic polymorphisms on the development of cardiotoxic complications. A total of 89 patients aged 18–78 years underwent electrocardiography, echocardiography, and molecular genetic testing for polymorphisms in GPX4, SOD2, COL1A1, CAT, EDN1, and COMT. Left ventricular hypertrophy (LVH) was detected in 58.4% of patients, reduced left ventricular ejection fraction (LVEF <50%) in 23.6%, arrhythmias in 46.1%, and ischemic changes in 28.1%. Increasing age was associated with LVH, reduced LVEF, and ischemic myocardial changes (p<0.05). Sex-specific differences showed a higher prevalence of rhythm disturbances in women and ischemic changes in men. Individual genetic polymorphisms were associated with specific cardiac phenotypes, while combined genetic risk (≥2 unfavourable alleles) was significantly associated with higher rates of LVH, arrhythmias, and impaired myocardial contractility. The findings support a polygenic model of cardiotoxicity and highlight the relevance of integrating demographic and genetic factors to enable personalised cardiovascular risk stratification and early prevention of cardiac complications.
1